Owkin joins UK digital pathology consortium PathLAKE to advance research and improve patient diagnostics

Duration:6 mins

Tags: AI / Diagnostics


Date:April 14th, 2023


Owkin joins UK digital pathology consortium PathLAKE to advance research and improve patient diagnostics

At Owkin, we build impactful digital pathology AI diagnostics to directly improve patient outcomes. In September last year, we launched RlapsRisk BC and MSIntuit CRC, our pioneering AI diagnostics designed to improve outcomes for patients with breast cancer and colorectal cancer.

To build on this success, we are pleased to announce that Owkin is joining PathLAKE, a consortium of the UK’s leading digital pathology innovators from within the NHS and across academia, as Associate Members. This partnership will enable more doctors and patients to benefit from our innovations while advancing Owkin’s ongoing diagnostics research efforts.

PathLAKE is a UK-based research consortium led by University Hospitals Coventry and Warwickshire NHS Trust dedicated to fostering innovation in digital pathology. By leveraging advanced technologies including AI, PathLAKE aims to improve diagnostic accuracy, streamline workflows, and facilitate the discovery of new insights in the field of pathology. As Associate Members, Owkin will be able to extend the reach of our AI diagnostics and empower more healthcare professionals to make data-driven decisions that enhance patient outcomes.

The digitization of pathology and advancements in machine learning have unlocked the potential for vast amounts of patient data to be analyzed at an unprecedented scale. Owkin's first-in-class AI diagnostics have been developed to help doctors to open up new treatment options, helping them to deliver precision medicine to their patients.

Our diagnostics analyze complex medical data, identifying patterns not immediately obvious to the human eye. This results in more precise diagnoses and personalized treatment plans, ultimately leading to better patient care.

We are grateful for the support of PathLAKE for our associate membership.

PathLAKE project director, Professor David Snead, said:

Owkin is pushing the boundaries of AI diagnostic research, developing solutions that have the potential to improve care for patients across the world. We are excited to welcome them as Associate Members of the PathLAKE consortium. By joining forces, we can accelerate the adoption of AI in pathology and transform the way doctors diagnose and treat patients. We look forward to a fruitful collaboration that will advance both research and care.

The collaboration between Owkin and PathLAKE will also contribute to the ongoing refinement of our solutions. By working closely with PathLAKE's network of digital pathology experts, Owkin aims to further hone our AI diagnostic tools, ensuring they remain at the forefront of innovation and continue to provide doctors with the most advanced solutions available.